Pollock, R. F., Heller, S., Pieber, T. R., Woo, V., Gundgaard, J., Hallén, N., . . . Zinman, B. (2019). Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes Obes Metab.

Pollock, Richard F., Simon Heller, Thomas R. Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas, and Bernard Zinman. "Short‐term Cost‐utility of Degludec Versus Glargine U100 for Patients With Type 2 Diabetes At High Risk of Hypoglycaemia and Cardiovascular Events: A Canadian Setting (DEVOTE 9)." Diabetes Obes Metab 2019.

Pollock, Richard F., et al. "Short‐term Cost‐utility of Degludec Versus Glargine U100 for Patients With Type 2 Diabetes At High Risk of Hypoglycaemia and Cardiovascular Events: A Canadian Setting (DEVOTE 9)." Diabetes Obes Metab 2019.